Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for approval of bempedoic acid (Nilemdo) for treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia

Bempedoic acid lowers low-density lipoprotein cholesterol by inhibiting cholesterol synthesis in the liver; and will be available as 180 mg film-coated tablets.


European Medicines Agency